Zimmer Biomet
977 hedge funds and large institutions have $23.6B invested in Zimmer Biomet in 2022 Q4 according to their latest regulatory filings, with 137 funds opening new positions, 294 increasing their positions, 332 reducing their positions, and 66 closing their positions.
108% more first-time investments, than exits
New positions opened: 137 | Existing positions closed: 66
44% more call options, than puts
Call options by funds: $50.5M | Put options by funds: $35.1M
20% more capital invested
Capital invested by funds: $19.6B → $23.6B (+$3.97B)
6% more funds holding
Funds holding: 919 → 977 (+58)
0.63% less ownership
Funds ownership: 89.51% → 88.88% (-0.63%)
7% less funds holding in top 10
Funds holding in top 10: 14 → 13 (-1)
11% less repeat investments, than reductions
Existing positions increased: 294 | Existing positions reduced: 332
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$161M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$140M |
| 3 |
Invesco
Atlanta,
Georgia
|
+$94M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$75.5M |
| 5 |
Capital Research Global Investors
Los Angeles,
California
|
+$75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$380M |
| 2 |
American Century Companies
Kansas City,
Missouri
|
-$88.4M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$86.9M |
| 4 |
Millennium Management
New York
|
-$77.3M |
| 5 |
CVA
Ceredex Value Advisors
Orlando,
Florida
|
-$67.2M |
ZBH Hedge Fund Activity: Q4 2022 in Review
977 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Zimmer Biomet (ZBH) for Q4 2022, worth a combined $23.6B — up 20% from $19.6B a quarter earlier.
Buyers outnumbered sellers: 137 funds opened new ZBH positions and 66 closed out — a net gain of 71 holders — while 294 added to existing stakes and 332 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $161M. The largest seller was JP Morgan Chase, cutting an estimated $380M.
- 977 institutional investors held Zimmer Biomet (ZBH) as of Q4 2022, up from 919 in Q3 2022.
- Funds reported $23.6B of Zimmer Biomet stock for Q4 2022, up 20% quarter-over-quarter.
- 137 funds opened new Zimmer Biomet positions in Q4 2022 and 66 closed out, a net change of +71 holders.
- The largest Zimmer Biomet buyer in Q4 2022 was Morgan Stanley, an estimated $161M added.
- The largest Zimmer Biomet seller in Q4 2022 was JP Morgan Chase, an estimated $380M sold.
Based on aggregated 13F filings for Q4 2022.